menu
    • menu
    [{"orgOrder":0,"company":"Nexgen Pharma, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Codeine Phosphate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Nexgen Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nexgen Pharma, Inc. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nexgen Pharma, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Nexgen Pharma, Inc.","sponsor":"Pharmaceutical Research Unit, Jordan","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Codeine Phosphate","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Nexgen Pharma, Inc.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nexgen Pharma, Inc. \/ Pharmaceutical Research Unit, Jordan","highestDevelopmentStatusID":"6","companyTruncated":"Nexgen Pharma, Inc. \/ Pharmaceutical Research Unit, Jordan"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"LaviPharm","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Boehringer Ingelheim GmbH \/ LaviPharm","highestDevelopmentStatusID":"15","companyTruncated":"Boehringer Ingelheim GmbH \/ LaviPharm"},{"orgOrder":0,"company":"Elite Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Elite Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elite Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elite Pharmaceuticals \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Codeine Phosphate

    Menu

    Codeine Phosphate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Elite Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Elite Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Codeine Phosphate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Elite Pharma Launches Acetaminophen and Codeine Tablets for Mild Pain Management

                            Details : Acetaminophen & codeine phosphate is a pain relief medicine. It is approved for use in adults for relief of mild to moderate pain & the management of moderate to severe pain.

                            Product Name : Tylenol-Generic

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2024

                            Lead Product(s) : Paracetamol,Codeine Phosphate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Boehringer Ingelheim GmbH

                            Germany arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Asset Purchase Agreement for Lavipharm

                            Details : Company acquires two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, used for fever and pain, for Greece and Cyprus markets with the intention to commercialize them internationally.

                            Product Name : Lonarid N

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 01, 2023

                            Lead Product(s) : Paracetamol,Caffeine,Codeine Phosphate

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : LaviPharm

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nexgen Pharma, Inc.

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nexgen Pharma, Inc.

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Codeine Phosphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Pharmaceutical Research Unit, Jordan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study

                            Details : Codeine Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 08, 2015

                            Lead Product(s) : Codeine Phosphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Pharmaceutical Research Unit, Jordan

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nexgen Pharma, Inc.

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Nexgen Pharma, Inc.

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Codeine Phosphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Trial of Extended Release Combination Tablet Codeine and Guaifenesin

                            Details : Codeine Phosphate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Cough.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 06, 2014

                            Lead Product(s) : Codeine Phosphate

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth